GPC3 and liver cancer: These data indicate that HN3 antibody bearing HLC9-EVs binds efficiently to the extracellular region of GPC3 expressed on the surface of Huh7 cells and thus conferring enhanced specific liver cancer cell targeting ability compared to control LC9-EVs.